Eocene Ltd. (EOCN)

Healthcare · Medical - Pharmaceuticals · NASDAQ · IL

$3.03-1.62%Close

COMPARE

EOCN

$3.03-1.62%

Overview Financials Earnings Analyst & RatingsAnalyst News Holders & ETFsHolders Options

RANGE

DATA 2026-10-23

LOPJLB.COM

OHLCOHLC, Essential layerEMAEMALEVELS, Essential layerSTOPStop, Essential layerFLIPFlip, Essential layer52W52-weekSIGNALS, Essential layerBUYBuy, Essential layerSELLSell, Essential layerEXHExhaustion, Essential layerEXH ZONEExhaustion zone, Essential layerCOILCoil

Oct 23, 2026O 3.11H 3.27L 2.96C 3.03-1.62%V 8.7K

Snapshot

Price & returns

1 week: +6.3%+6.7% vs SPY
1 month: -16.3%-15.3% vs SPY

Valuation

Market cap: $3.2M

Short interest & options

Short % float: 1.4%
Days to cover: 2.0
Short change: +26.2%

Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year

Price & returns: 3 years, 5 years

Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)

Signal evidence

How it works

Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)

Lists

Quality dividend stocks

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

About

Eocene Ltd. (EOCN). Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquart…

SEC filingsCIK 1595353